Ahmedabad, India – 3rd December 2024: Cadila Pharmaceuticals proudly commemorates the first anniversary of its advanced Active Pharmaceutical Ingredients (API) manufacturing facility in Dahej, Gujarat. Inaugurated on November 26, 2023, this cutting-edge plant underscores the company’s commitment to innovation, efficiency, and sustainability in pharmaceutical production.
Established with an investment of INR 230 crore, the Dahej plant is part of Cadila Pharmaceuticals’ broader strategy to invest INR 1,000 crore under a Memorandum of Understanding (MoU) with the Gujarat Government. The facility features advanced Distributed Control System (DCS) automation, ensuring high-quality production standards and adherence to environmental best practices.
Key Highlights of the Dahej Facility:
Investment: INR 230 crore as a component of the company’s INR 1,000 crore expansion initiative.
Technology: DCS automation for precise, efficient, and sustainable API manufacturing processes.
Impact: Strengthened domestic API production capabilities, reducing import dependence and bolstering global supply chain resilience.
Employment Generation: Significant contribution to local employment, supporting economic growth in the region.
The completion of this first year reflects Cadila Pharmaceuticals’ commitment to providing innovative and affordable healthcare solutions while maintaining the highest production and environmental standards. The Dahej facility plays a pivotal role in fulfilling global demand for APIs, contributing to the healthcare ecosystem both domestically and internationally.
As Cadila Pharmaceuticals celebrates this milestone, the company looks forward to scaling new heights and delivering on its vision of making quality healthcare accessible worldwide.
